Category: Psychedelics
-
Revive (RVV.C) advances drug delivery tech for psychedelics
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
-
Shroom Digest: Mushroom moves from MindMed, Yield Growth, New Wave, Yukoterre, Silo, EGF Theramed
This week’s digest of mushroom moves is a mixed bag of trash and glory, with the shrooms sector increasingly looking like the early days of the cannabis rush.
-
Revive Therapeutics’ (RVV.C) product pipeline is flowing freakishly fast
Revive Therapeutics is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (Covid-19)
-
Revive Therapeutics (RVV.C): Kicked around, called a fraud, gets FDA approval of Phase 3 COVID-19 trials
“Let them say what they want, we know what we’re doing, and we’re doing the work,” Michael Frank told me a month ago, as he put out news claiming his little pharma company, which had built a reputation for chasing aggressively into new pharmaceutical fields, had found some IP that might be useful in the…
-
Revive Therapeutics (RVV.C) warned about overhype, but up 26% on clinical trial news
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts…
-
Revive Therapeutics (RVV.C) finds pharma asset under the couch that may treat COVID-19
When new sectors emerge, as cannabis did in 2013 and psychedelics are doing right now, microcap companies that have struggled in other sectors will often pivot into new business. Miners become weed companies, then biotech companies, then shroom companies, as boards and management pursue new opportunities that might one day prove better than the last.
-
AMPD, PAT, MTA, HIVE, MILE: Contrarian investing as the zombies climb over the walls
Okay, so the world is burning, the Russians and Saudis are pouring low-cost fuel over it, the Americans are shocked that a reality TV show host with a penchant for scams didn’t make a clever President, Italy is in total lockdown, the Japanese are thinking of holding a spectator-free Olympics, Israel is putting anyone coming…
-
Shroom stocks go nuts: First movers SHRM, MMED, RVV up hard as gamblers gamble
Today was a day that daytraders have been looking forward to for some time; the day that shroom stocks finally gripped the road and took off. Mind Medicine (MMED.E) ripped 90% to $0.77 on the back of 15m shares traded, reminding anyone who’d listen that ex-Canopy CEO Bruce Linton and pretend billionaire Kevin O’Leary were on…
-
![Yield Growth (BOSS.C) looks into 2020 crystal ball and sees a shroom boom]()
Yield Growth (BOSS.C) looks into 2020 crystal ball and sees a shroom boom
Through its subsidiaries, Yield Growth has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. It has filed 13 patents to protect its extraction method and IP. Yield Growth earns revenue through multiple streams including licensing, services and product sales.
-
![OK boomer: In which I come to Jesus over mushrooms and put my dollars into Absolem]()
OK boomer: In which I come to Jesus over mushrooms and put my dollars into Absolem
50 years I’ve been bumbling around this planet, and the best damn weekend I’ve had on it to date occurred recently, under the influence of mushrooms. The carpet didn’t talk to me and the walls weren’t bleeding, and the sunrise wasn’t the incarnation of Shiva. That ain’t it, kids. No, what happened is my head…
